Will Masimo Integration and Bioprocessing Strength Change Danaher's (DHR) Diagnostics-Driven Narrative?

Simply Wall St.07-18 19:22

Danaher recently benefited from optimism around its July 21 Q2 2026 earnings release, with analysts expecting modest revenue and earnings growth supported by strength in bioprocessing and filtration, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652723455?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","is_english":true,"pubTime":"2026-07-18 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652723455","market":"hk","top_or_hot":-1,"title":"Will Masimo Integration and Bioprocessing Strength Change Danaher's (DHR) Diagnostics-Driven Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Danaher recently benefited from optimism around its July 21 Q2 2026 earnings release, with analysts expecting modest revenue and earnings growth supported by strength in bioprocessing and filtration, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/will-masimo-integration-and-bioprocessing-strength-change-da\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Masimo Integration and Bioprocessing Strength Change Danaher's (DHR) Diagnostics-Driven Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Masimo Integration and Bioprocessing Strength Change Danaher's (DHR) Diagnostics-Driven Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-18 19:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/will-masimo-integration-and-bioprocessing-strength-change-da><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Danaher recently benefited from optimism around its July 21 Q2 2026 earnings release, with analysts expecting modest revenue and earnings growth supported by strength in bioprocessing and filtration, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/will-masimo-integration-and-bioprocessing-strength-change-da\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2355687059.USD","symbol_name":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/will-masimo-integration-and-bioprocessing-strength-change-da","article_id":"2652723455","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/will-masimo-integration-and-bioprocessing-strength-change-da","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652723455","pubTimestamp":1784373778,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Danaher recently benefited from optimism around its July 21 Q2 2026 earnings release, with analysts expecting modest revenue and earnings growth supported by strength in bioprocessing and filtration, plus contributions from acquisitions like Masimo and Leica Biosystems’ agreement to acquire StatLab Medical Products.\nInvestors are increasingly focused on how these diagnostics-expanding deals and bioprocessing momentum might offset ongoing cost pressures, high debt levels, and softness in...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","FMED":"Fidelity Disruptive Medicine ETF","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1923621640.USD":"Natixis Thematics Water R/A USD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4082":"医疗保健设备","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","MASI":"麦斯莫医疗","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BMED":"iShares Health Innovation Active ETF","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4581":"高盛持仓","BK4121":"生命科学工具和服务","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","DHR.AU":"Dark Horse Resources","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","DHR":"丹纳赫","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","LU2063271972.USD":"富兰克林创新领域基金","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC"},"translate_title":"Masimo 集成和生物加工实力会改变丹纳赫 (DHR) 诊断驱动的叙事吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FMED":0.6,"MASI":1.5,"BMED":0.72,"DHR":1.5,"DHR.AU":1.5},"content_text":"Danaher recently benefited from optimism around its July 21 Q2 2026 earnings release, with analysts expecting modest revenue and earnings growth supported by strength in bioprocessing and filtration, plus contributions from acquisitions like Masimo and Leica Biosystems’ agreement to acquire StatLab Medical Products. Investors are increasingly focused on how these diagnostics-expanding deals and bioprocessing momentum might offset ongoing cost pressures, high debt levels, and softness in parts of the Diagnostics segment. Now we’ll examine how Masimo’s integration into Danaher’s diagnostics portfolio could reshape the company’s broader investment narrative and risk profile. The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementDanaher Investment Narrative RecapTo own Danaher, you generally need to believe in its ability to compound cash flows from diagnostics and life sciences tools, supported by recurring consumables revenue and disciplined execution under the Danaher Business System. The latest optimism around Q2 2026, helped by Masimo and StatLab, mainly reinforces the near term focus on whether bioprocessing and filtration strength can balance cost pressure and higher debt, while ongoing Diagnostics softness and governance questions remain key risks. Among recent developments, Leica Biosystems’ agreement to acquire StatLab Medical Products looks most relevant, as it directly expands Danaher’s diagnostics and anatomical pathology reach just as investors are gauging how Masimo’s integration and bioprocessing demand can support earnings and cash flow. Together, these portfolio moves keep diagnostics at the center of the current catalyst debate, particularly around how much they can counter higher input, operating, and interest expenses tied to new debt issued for acquisitions. Yet against this backdrop of growing diagnostics capabilities, investors should still pay close attention to the rising debt load and its potential impact on... Read the full narrative on Danaher (it's free!)Danaher’s narrative projects $31.2 billion revenue and $6.5 billion earnings by 2029. This requires 8.0% yearly revenue growth and about a $2.8 billion earnings increase from $3.7 billion today.Uncover how Danaher's forecasts yield a $242.35 fair value, a 19% upside to its current price.Exploring Other PerspectivesDHR 1-Year Stock Price Chart Five Simply Wall St Community valuations for Danaher span about US$187 to US$261.95 per share, underlining how far apart individual views can be. You can weigh these against the current focus on bioprocessing strength and Masimo driven diagnostics expansion, and consider how such differing expectations might influence the company’s future risk and return profile.Explore 5 other fair value estimates on Danaher - why the stock might be worth 8% less than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Danaher research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Danaher research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Danaher's overall financial health at a glance.No Opportunity In Danaher?Every day counts. These free picks are already gaining attention. See them before the crowd does:Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.Uncover the next big thing with 20 elite penny stocks that balance risk and reward.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652723455","isCrawlerRequest":true}